Pazopanib Export Market Intelligence: India's 109 Suppliers Shipping to 57 Countries — TransData Nexus 2026

Q: Who are the top pazopanib exporters from India?

The top pazopanib exporters from India are: 1. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $5.6M (66.6% market share); 2. SP ACCURE LABS PRIVATE LIMITED — $306.7K (3.7% market share); 3. TEYRO LABS PRIVATE LIMITED — $282.3K (3.4% market share); 4. GNH INDIA PHARMACEUTICALS LIMITED — $185.6K (2.2% market share); 5. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED — $92.0K (1.1% market share). Together they account for 77.0% of India's total pazopanib export value.

Q: What is the total export value of pazopanib from India?

The total export value of pazopanib from India is $8.3M USD, recorded across 498 shipment transactions from 109 active exporters to 57 destination countries. The average shipment value is $16.8K.

Q: Which countries import pazopanib from India?

India exports pazopanib to 57 countries worldwide. The top importing countries are: UNITED STATES (84.4% share, $7.0M), GEORGIA (2.6% share, $212.9K), TAIWAN (2.3% share, $192.9K), SRI LANKA (1.9% share, $161.5K), BELARUS (1.8% share, $150.1K). These five markets account for 93.0% of total export value.

Q: What is the HS code for pazopanib exports from India?

The primary HS code for pazopanib exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of pazopanib exports from India?

The average unit price for pazopanib exports from India is $67.65 USD per unit, with prices ranging from $0.01 to $836.03 depending on formulation, packaging, and order volume. The total market is valued at $8.3M across 498 shipments.

Q: Which ports handle pazopanib exports from India?

The primary ports for pazopanib exports from India are SAHAR AIR CARGO ACC (INBOM4) (24.3% of shipments), SAHAR AIR (20.7% of shipments), DELHI AIR (9.6% of shipments), DELHI AIR CARGO ACC (INDEL4) (8.2% of shipments), Bombay Air (4.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of pazopanib?

India is one of the world's leading exporters of pazopanib due to its large base of 109 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports pazopanib to 57 countries, demonstrating 29% global market coverage.

Q: What certifications do Indian pazopanib exporters need?

Indian pazopanib exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import pazopanib from India?

There are 196 registered buyers importing pazopanib from India, spread across 57 countries. The repeat buyer rate is 46.9%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top pazopanib supplier from India?

SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading pazopanib exporter from India with a market share of 66.6% and total export value of $5.6M across 9 shipments. The top 5 suppliers together control 77.0% of total export value.

Suresh Sormare

Pazopanib

India Pharmaceutical Trade Intelligence

$8.3M109 Suppliers57 CountriesHS 30049049

ExportsIndia → UNITED STATES84.4%India → GEORGIA2.6%

ImportsUNITED KINGDOM → India$3.3M SWITZERLAND → India$596.6K

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: SUN PHARMACEUTICAL

Pazopanib Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Pazopanib to the World

Between 2022 and 2026, India exported $8.3M worth of pazopanib across 498 verified shipments to 57 countries — covering 29% of world markets in the Advanced Oncology segment. The largest destination is UNITED STATES (84.4%). SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 66.6% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Pazopanib export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Pazopanib export data snapshot — $8.3M · 109 exporters · 57 countriesTransData Nexus · Indian Customs Data

Top Pazopanib Exporters from India

109 active exporters · Ranked by export value

View all 109 →

Top Pazopanib Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$5.6M	9	2	66.6%
2	SP ACCURE LABS PRIVATE LIMITED

Top Countries Importing Pazopanib from India

57 destination markets · Ranked by import value

All 57 countries →

Top Countries Importing Pazopanib from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$7.0M	84.4%
2	GEORGIA	$212.9K	2.6%
3	TAIWAN	$192.9K	2.3%
4	SRI LANKA	$161.5K	1.9%
5	BELARUS	$150.1K	1.8%
6	RUSSIA	$92.0K	1.1%
7	BOLIVIA	$58.4K	0.7%
8	THAILAND	$52.6K	0.6%
9	TURKEY	$46.0K	0.6%
10	YEMEN	$33.3K	0.4%

UNITED STATES is India's largest pazopanib export destination, absorbing 84.4% of total exports worth $7.0M. The top 5 importing countries — UNITED STATES, GEORGIA, TAIWAN, SRI LANKA, BELARUS — together account for 93.0% of India's total pazopanib export value. The remaining 52 destination countries collectively receive the other 7.0%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Pazopanib to India?

17 origin countries · Total import value: $4.5M

India imports pazopanib from 17 countries with a combined import value of $4.5M. The largest supplier is UNITED KINGDOM ($3.3M, 13 shipments), followed by SWITZERLAND and IRELAND. All values are from Indian Customs (DGFT) import records.

Countries Supplying Pazopanib to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED KINGDOM	$3.3M	13	73.6%
2	SWITZERLAND	$596.6K	2	13.2%
3	IRELAND	$225.0K	2	5.0%
4	UNITED STATES	$168.6K	4	3.7%
5	GERMANY	$55.4K	4	1.2%
6	BRAZIL	$46.5K	4	1.0%
7	BULGARIA	$36.6K	2	0.8%
8	CANADA	$31.5K	2	0.7%
9	AUSTRALIA	$12.9K	2	0.3%
10	DENMARK	$7.1K	3	0.2%

Showing top 10 of 17 origin countries

UNITED KINGDOM is the largest supplier of pazopanib to India, accounting for 73.6% of total import value. The top 5 origin countries — UNITED KINGDOM, SWITZERLAND, IRELAND, UNITED STATES, GERMANY — together supply 96.7% of India's pazopanib imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Pazopanib

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, the Food and Drug Administration (FDA) regulates the approval and importation of pharmaceuticals, including pazopanib. The FDA's Orange Book lists approved drug products and their therapeutic equivalence evaluations. As of March 2026, several Abbreviated New Drug Applications (ANDAs) for generic versions of pazopanib have been approved, indicating a competitive market landscape. Notably, the FDA approved an ANDA for a generic version of pazopanib in June 2025, enhancing market competition.

Given that 84.4% of India's pazopanib exports are directed to the United States, it is imperative for Indian exporters to ensure compliance with FDA regulations. This includes adherence to Current Good Manufacturing Practices (cGMP) and maintaining rigorous quality control measures to avoid import alerts or detentions. The presence of 109 active Indian exporters underscores the importance of stringent regulatory compliance to sustain market access.

2EU & UK Regulatory Framework

In the European Union (EU) and the United Kingdom (UK), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively, oversee the approval and monitoring of pharmaceuticals. Pazopanib has been granted marketing authorization in the EU, subject to compliance with EU Good Manufacturing Practice (GMP) standards. Similarly, the MHRA requires adherence to UK GMP regulations for pazopanib marketed within the UK.

While the primary export destinations for Indian-manufactured pazopanib are outside the EU and UK, Indian exporters targeting these markets must ensure compliance with the respective regulatory requirements, including obtaining necessary marketing authorizations and adhering to GMP standards.

3WHO Essential Medicines & Global Standards

The World Health Organization (WHO) maintains the Model List of Essential Medicines (EML), which guides countries in developing their national essential medicines lists. As of the 24th edition published in September 2025, pazopanib is not included in the WHO EML. However, it is essential for exporters to be aware of international pharmacopoeia standards, such as those set by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure global quality compliance.

4India Regulatory Classification

In India, the Central Drugs Standard Control Organization (CDSCO) classifies pharmaceuticals to regulate their distribution and use. Pazopanib is categorized under Schedule H, indicating that it is a prescription drug requiring a valid prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) oversees drug pricing; however, as of March 2026, pazopanib is not listed under the Drug Price Control Order (DPCO), meaning it does not have a government-mandated ceiling price. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

5Patent & Exclusivity Status

Pazopanib was initially patented by GlaxoSmithKline, with the primary patent expiring in 2023. The expiration has led to increased generic competition, as evidenced by the approval of multiple ANDAs by the FDA. This competitive landscape necessitates that Indian exporters focus on maintaining high-quality standards and cost-effective production to remain competitive in the global market.

6Recent Industry Developments

In June 2025, the FDA approved an ANDA for a generic version of pazopanib, signaling increased competition in the U.S. market. In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, which did not include pazopanib. In October 2025, the NPPA conducted a review of oncology drug prices, though pazopanib remained outside the purview of price control under the DPCO. In December 2025, the EMA issued updated guidelines on GMP compliance for manufacturers exporting to the EU, emphasizing the need for stringent quality control measures. In February 2026, the CDSCO announced a streamlined process for obtaining export NOCs, aiming to facilitate pharmaceutical exports while ensuring regulatory compliance.

These developments underscore the dynamic nature of the regulatory landscape for pazopanib. Indian exporters must stay abreast of regulatory changes and market dynamics to ensure continued access to key markets and maintain a competitive edge.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Pazopanib

Retail & reference prices across 9 markets vs. India FOB export price of $67.65/unit

Global Price Benchmark for Pazopanib across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$200	USD	According to the FDA's Orange Book, Votrient is an approved medication in the U.S.
United Kingdom	$195	GBP	As per the NHS Drug Tariff, Votrient is listed for use within the NHS.
Germany	$200	EUR	The European Medicines Agency (EMA) has approved Votrient for use in Germany.
Australia	$175	AUD

Supply Chain Risk Assessment — Pazopanib

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

Pazopanib, an antineoplastic agent primarily used in the treatment of renal cell carcinoma, relies heavily on Active Pharmaceutical Ingredients (APIs) manufactured in India. However, the production of these APIs is intricately linked to Key Starting Materials (KSMs) and intermediates, a significant portion of which are imported from China. This dependency poses a strategic chokepoint in the supply chain, as any disruption in the availability of these KSMs can halt API synthesis, leading to potential shortages of the final pharmaceutical product.

Recent analyses have highlighted the vulnerabilities associated with this reliance. A report from the U.S. Pharmacopeia in October 2025 indicated that 58% of KSMs used for U.S.-approved APIs are sourced from a single country, with China accounting for 41% and India for 16%. This concentration underscores the risk of supply chain disruptions due to geopolitical tensions, trade restrictions, or manufacturing issues in these countries.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 reveals a significant concentration in the export of Pazopanib from India. The top five exporters account for 77.0% of the total export value, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 66.6% ($5.6 million USD). This high level of supplier concentration introduces a substantial single-source risk; any operational or compliance issues within these leading firms could severely impact the global supply of Pazopanib.

Access Complete Pazopanib Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 498 transactions across 57 markets.

Request Demo View Pricing

Frequently Asked Questions — Pazopanib Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top pazopanib exporters from India?

The leading pazopanib exporters from India are SUN PHARMACEUTICAL INDUSTRIES LIMITED, SP ACCURE LABS PRIVATE LIMITED, TEYRO LABS PRIVATE LIMITED, and 7 others. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 66.6% market share ($5.6M). The top 5 suppliers together control 77.0% of total export value.

What is the total export value of pazopanib from India?

The total export value of pazopanib from India is $8.3M, recorded across 498 shipments from 109 active exporters to 57 countries. The average shipment value is $16.8K.

Which countries import pazopanib from India?

India exports pazopanib to 57 countries. The top importing countries are UNITED STATES (84.4%), GEORGIA (2.6%), TAIWAN (2.3%), SRI LANKA (1.9%), BELARUS (1.8%), which together account for 93.0% of total export value.

What is the HS code for pazopanib exports from India?

The primary HS code for pazopanib exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Pazopanib

Pazopanib

Top Pazopanib Exporters from India

Top Countries Importing Pazopanib from India

Who Supplies Pazopanib to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Pazopanib

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Pazopanib

Supply Chain Risk Assessment — Pazopanib

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Pazopanib Trade Intelligence

Frequently Asked Questions — Pazopanib Exports from India

Who are the top pazopanib exporters from India?

What is the total export value of pazopanib from India?

Which countries import pazopanib from India?

What is the HS code for pazopanib exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of pazopanib exports from India?

Which ports handle pazopanib exports from India?

Why is India a leading exporter of pazopanib?

What certifications do Indian pazopanib exporters need?

How many buyers import pazopanib from India?

What is the market share of the top pazopanib exporter from India?

Analysis Methodology